

**Table S1. GPP and plaque psoriasis characteristics stratified by disease severity, defined by BSA**

Characteristic	GPP <3% BSA	GPP <3% BSA sample size	Plaque psoriasis <3% BSA	Plaque psoriasis <3% BSA sample size	GPP ≥3% BSA	GPP ≥3% BSA sample size	Plaque psoriasis ≥3% BSA	Plaque psoriasis ≥3% BSA sample size
<b>Demographics</b>								
Age, years, mean (SD)	47.0 (14.6)	20	50.1 (14.0)	1774	52.9 (14.0)	40	50.9 (14.4)	3107
Sex, female, n (%)	16 (80.0)	20	803 (45.3)	1774	20 (50.0)	40	1364 (43.9)	3107
Education, n (%)		20		1770		39		
High school graduate/GED	8 (40.0)		409 (23.1)		15 (38.5)		777 (25.1)	3099
College graduate or higher	7 (35.0)		714 (40.3)		14 (35.9)		1123 (36.2)	
Work status, n (%)		20		1771		40		3102
Full-time	10 (50.0)		1128 (63.7)		21 (52.5)		1792 (57.7)	
Part-time	-		152 (8.6)		-		246 (7.9)	
Retired	-		270 (15.2)		7 (17.5)		510 (16.4)	
Disabled	-		101 (5.7)		8 (20.0)		264 (8.5)	
Other	-		120 (6.8)		-		290 (9.3)	
Current smoker, n (%)	-	19	287 (16.3)	1757	8 (20.0)	40	534 (17.4)	3074
BMI, n (%)		19		1744		40		3069
≤24.9	-		372 (21.3)		5 (12.5)		554 (18.1)	
25–29.9	-		570 (32.7)		12 (30.0)		915 (29.8)	
≥30	12 (63.2)		802 (46.0)		23 (57.5)		1600 (52.1)	
<b>Disease characteristics</b>								
Psoriasis duration, years		20		1754		40		3081
Mean (SD)	11.6 (11.1)		15.3 (13.7)		12.3 (12.8)		14.2 (13.3)	
Median (IQR)	6.5 (2.5–24.0)		11.0 (4.0–24.0)		9.5 (2.0–20.0)		10.0 (3.0–21.0)	
Psoriatic arthritis, n (%)	13 (65.0)	20	631 (36.5)	1727	14 (35.0)	40	1037 (34.3)	3022
PEST 3+, n (%)	10 (50.0)	20	512 (28.9)	1774	13 (32.5)	40	820 (26.4)	3107
BSA continuous		20		1774		40		3107
Mean (SD)	0.8 (0.7)		0.8 (0.8)		18.7 (16.0)		15 (15.2)	
Median (IQR)	1.0 (0.0–1.0)		1.0 (0.0–1.0)		12.0 (6.5–30.0)		10.0 (5.0–19.0)	

<b>PASI (range 0–72), n (%)</b>		20		1773		40		3105
<b>≤10</b>	20 (100.0)		1773 (100.0)		30 (75.0)		2231 (71.9)	
<b>&gt;10</b>	-		-		10 (25.0)		874 (28.1)	
<b>IGA category, n (%)</b>		20		1773		40		3104
<b>0: Clear</b>	6 (30.0)		690 (38.9)		-		11 (<1.0)	
<b>1: Almost clear</b>	9 (45.0)		590 (33.3)		-		221 (7.1)	
<b>2: Mild</b>	-		353 (19.9)		14 (35.0)		775 (25.0)	
<b>3: Moderate</b>	-		120 (6.8)		21 (52.5)		1655 (53.3)	
<b>4: Severe</b>	-		20 (1.1)		-		442 (14.2)	
<b>Infections, n (%)</b>		20		1774		40		3106
<b>All</b>	10 (50.0)		483 (27.2)		19 (47.5)		850 (27.4)	
<b>Serious</b>	-		58 (3.3)		6 (15.0)		135 (4.3)	
<b>Selected pathogens</b>	-		84 (4.7)		5 (12.5)		178 (5.7)	
<b>Hypertension, n (%)</b>	6 (30.0)	20	584 (33.0)	1771	22 (55.0)	40	1211 (39.0)	3105
<b>Other CVD (e.g. stroke) , n (%)</b>	-	20	93 (5.2)	1774	-	40	203 (6.5)	3107
<b>Hyperlipidemia, n (%)</b>	8 (40.0)	20	408 (23.0)	1771	8 (20.0)	40	819 (26.4)	3105
<b>Diabetes mellitus, n (%)</b>	-	20	203 (11.5)	1771	10 (25.0)	40	503 (16.2)	3105
<b>Asthma, n (%)</b>	-	20	99 (5.6)	1771	5 (12.5)	40	186 (6.0)	3105
<b>Depression, n (%)</b>	9 (45.0)	20	275 (15.5)	1771	10 (25.0)	40	556 (17.9)	3105
<b>Anxiety, n (%)</b>	8 (40.0)	20	282 (15.9)	1771	9 (22.5)	40	551 (17.7)	3105
<b>Treatment, n (%)</b>								
<b>Biologic exposure, n (%)</b>		20		1774		40		3107
<b>Bio-naïve</b>	5 (25.0)		962 (54.2)		19 (47.5)		1691 (54.4)	
<b>1 previous</b>	6 (30.0)		425 (24.0)		15 (37.5)		740 (23.8)	
<b>≥2 previous</b>	9 (45.0)		387 (21.8)		6 (15.0)		676 (21.8)	
<b>Non-biologic systemic exposure, n (%)</b>		20		1774		40		3107
<b>Systemic naïve</b>	-		1055 (59.5)		16 (40.0)		1899 (61.1)	
<b>1 previous</b>	-		596 (33.6)		18 (45.0)		1003 (32.3)	
<b>≥2 previous</b>	-		123 (6.9)		6 (15.0)		205 (6.6)	
<b>Phototherapy, n (%)</b>	12 (60.0)	20	696 (39.2)	1774	14 (35.0)	40	1257 (40.5)	3106
<b>Current therapy, n (%)</b>		19		1594		25		1698
<b>TNFi</b>	-		390 (24.5)		6 (24.0)		486 (28.6)	
<b>Non-TNFi biologic</b>	12 (63.2)		1116 (70.0)		14 (56.0)		915 (53.9)	

<b>Systemic non-biologic</b>	-		88 (5.5)		5 (20.0)		297 (17.5)	
<b>Patient-reported outcomes</b>								
<b>Itch VAS (range 0–100)</b>		20		1773		40		3101
<b>Mean (SD)</b>	35.2 (39.1)		16.2 (25.0)		53.9 (34.5)		46.4 (34.1)	
<b>Median (IQR)</b>	16.0 (0.5–68.0)		5.0 (0.0–20.0)		66.0 (17.0–85.0)		50.0 (10.0–77.0)	
<b>Fatigue VAS (range 0–100)</b>		20		1771		40		3101
<b>Mean (SD)</b>	33.6 (32.6)		22.2 (25.4)		47.0 (29.8)		33.6 (29.2)	
<b>Median (IQR)</b>	28.0 (2.5–50.0)		10.0 (0.0–40.0)		50.0 (20.0–77.0)		30.0 (5.0–55.0)	
<b>Pain VAS (range 0–100)</b>		20		1771		40		3099
<b>Mean (SD)</b>	25.7 (34.4)		8.3 (17.5)		36.8 (33.9)		29.0 (31.4)	
<b>Median (IQR)</b>	7.5 (0.0–48.0)		0.0 (0.0–5.0)		25.0 (3.5–69.0)		15.0 (0.0–50.0)	
<b>PGA</b>		20		1771		40		3098
<b>Mean (SD)</b>	31.8 (32.1)		19.8 (24.3)		52.6 (28.6)		45.1 (29.2)	
<b>Median (IQR)</b>	20.0 (4.0–58.0)		10.0 (3.0–25.0)		54.0 (25.0–80.0)		50.0 (20.0–70.0)	
<b>Currently employed, n (%)</b>	12 (60.0)	20	1278 (72.0)	1774	23 (57.5)	40	2050 (66.0)	3106
<b>Percent work hours missed</b>		10		1142		19		1852
<b>Mean (SD)</b>	6.2 (12.4)		2.3 (11.6)		9.4 (13.4)		4 (14.8)	
<b>Median (IQR)</b>	0.0 (0.0–7.0)		0.0 (0.0–0.0)		0.0 (0.0–20.0)		0.0 (0.0–0.0)	
<b>Percent overall work hours affected</b>		10		1129		40		1832
<b>Mean (SD)</b>	16.5 (22.2)		6.3 (15.3)		27.4 (23.3)		14.3 (21.9)	
<b>Median (IQR)</b>	2.5 (0.0–35.0)		0.0 (0.0–5.0)		20.0 (10.0–50.0)		3.0 (0.0–20.0)	
<b>Percent daily activity impairment</b>		20		1761		40		3076
<b>Mean (SD)</b>	35.0 (38.8)		9.6 (19.9)		30.3 (29.9)		21.4 (27.3)	
<b>Median (IQR)</b>	20.0 (0.0–73.0)		0.0 (0.0–10.0)		20.0 (2.5–55.0)		8.0 (0.0–40.0)	
<b>DLQI score (range 0–30)</b>								
<b>Mean (SD)</b>	6.5 (6.4)		4.3 (5.5)		8.4 (7.0)		7.7 (6.0)	
<b>Median (IQR)</b>	3.0 (1.0–13.0)		2.0 (0.0–6.0)		5.0 (3.0–15.0)		6.0 (3.0–12.0)	
<b>'Effect on life', n (%)</b>		20		1769		40		3100
<b>0: None</b>	6 (30.0)		777 (43.9)		-		424 (13.7)	
<b>1: Small</b>	-		503 (28.4)		17 (42.5)		976 (31.5)	
<b>2: Moderate</b>	-		245 (13.8)		6 (15.0)		763 (24.6)	
<b>3: Very large</b>	7 (35.0)		186 (10.5)		11 (27.5)		824 (26.6)	
<b>4: Extremely large</b>	-		58 (3.3)		-		113 (3.6)	

<b>Patient health state today</b>		20		1767		40		3097
<b>EQ-5D VAS (range 0–100)</b>								
<b>Mean (SD)</b>	61.5 (26.2)		78.6 (19.2)		64.3 (22.8)		71.2 (21.3)	
<b>Median (IQR)</b>	59.0 (50.0–90.0)		85.0 (70.0–90.0)		70.0 (50.0–82.0)		75.0 (60.0–90.0)	
<b>EQ-5D-3L, n (%)</b>		20		1749		40		3072
<b>Walking</b>	8 (40.0)		335 (19.2)		13 (32.5)		766 (24.9)	
<b>Self-care</b>	-		81 (4.6)		10 (25.0)		206 (6.7)	
<b>Usual activities</b>	10 (50.0)		367 (21.0)		16 (40.0)		881 (28.7)	
<b>Pain/discomfort</b>	13 (65.0)		654 (37.4)		29 (72.5)		1637 (53.3)	
<b>Anxiety/depression</b>	10 (50.0)		364 (20.8)		13 (32.5)		876 (28.5)	

*BMI, body mass index; BSA, body surface area; CVD, cardiovascular disease; DLQI, Dermatology Life Quality Index; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels; GED, General Education Development; GPP, generalized pustular psoriasis; IGA, Investigator Global Assessment; IQR, interquartile range; PASI, Psoriasis Area Severity Index; PEST, Psoriasis Epidemiology Screening Tool; PGA, Patient Global Assessment; SD, standard deviation; TNFi, tumor necrosis factor inhibitor; VAS, visual analog scale. Only comorbidities with >5% incidence are shown. Categories are not an exhaustive list due to the small sample size*

